=== chr6:32581719C>T Genomic Analysis Report ===


#VARIANT INFO:


DETAILED VARIANT INFORMATION:
=============================
• rsID: rs757966595
• Chromosome: 6
• Position: 32581719
• Reference Allele (REF): C
• Alternative Allele (ALT): T
• Genotype: 1|0
• Quality Score: N/A
• Gene Names: HLA-DRB1
• Databases: rs757966595, COSV108197821

CLINICAL ANNOTATIONS:
====================
• ClinVar Significance: uncertain_significance
• ACMG Classification: Benign
• OMIM: True

POPULATION FREQUENCIES:
======================
• gnomAD Allele Frequency: 0.0018219999999999998
• gnomADg Allele Frequency: 0.008761
• 1KG Frequency: N/A

SEQUENCING DATA:
================
• Depth (DP): N/A
• Allelic Depth (AD): [-1, -1]


# GWAS INFO
GWAS ASSOCIATIONS DATABASE:
GWAS_EFO_0000270: obsolete_asthma - A chronic respiratory disease manifested as difficulty breathing due to the narrowing of bronchial passageways.|Tendency of the smooth muscle of the tracheobronchial tree to contract more intensely in response to a given stimulus than it does in the response seen in normal individuals. This condition is present in virtually all symptomatic patients with asthma. The most prominent manifestation of this smooth muscle contraction is a decrease in airway caliber that can be readily measured in the pulmonary function laboratory.|A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).|A bronchial disease that is characterized by chronic inflammation and narrowing of the airways, which is caused by a combination of environmental and genetic factors resulting in recurring periods of wheezing (a whistling sound while breathing), chest tightness, shortness of breath, mucus production and coughing. The symptoms appear due to a variety of triggers such as allergens, irritants, respiratory infections, weather changes, excercise, stress, reflux disease, medications, foods and emotional anxiety.
GWAS_EFO_0007937: blood protein measurement - quantification of the levels of some protein in a blood sample
GWAS_EFO_0007034: seropositivity measurement - a seropositivity measurement is the quantification of an individual's exposure to a certain pathogen through the presence or absence in blood of pathogen specific circulating antibodies|
GWAS_EFO_0007969: cognitive inhibition measurement - quantification of cognitive inhibition or executive inhibition in an individual with ADHD, measured for example using the Stroop test
GWAS_EFO_0005854: allergic rhinitis - Inflammation of the nasal mucous membranes caused by an IgE-mediated response to external allergens. The inflammation may also involve the mucous membranes of the sinuses, eyes, middle ear, and pharynx. Symptoms include sneezing, nasal congestion, rhinorrhea, and itching. It may lead to fatigue, drowsiness, and malaise thus causing impairment of the quality of life.
GWAS_HP_0000964: Eczema - Eczema is a form of dermatitis. The term eczema is broadly applied to a range of persistent skin conditions and can be related to a number of underlying conditions. Manifestations of eczema can include dryness and recurring skin rashes with redness, skin edema, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding.|Eczema has several forms including atopic dermatitis, contact dermatitis, dyshidrotic eczema, nummular eczema, seborrheic dermatitis, and stasis dermatitis.
GWAS_EFO_0000692: obsolete_schizophrenia - A major psychotic disorder characterized by abnormalities in the perception or expression of reality. It affects the cognitive and psychomotor functions. Common clinical signs and symptoms include delusions, hallucinations, disorganized thinking, and retreat from reality.|A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
GWAS_EFO_0003756: autism spectrum disorder - A spectrum of developmental disorders that includes autism, and Asperger syndrome. Signs and symptoms include poor communication skills, defective social interactions, and repetitive behaviors.|A pervasive developmental disease that is a spectrum of psychological conditions characterized by widespread abnormalities of social interactions and communication, as well as severely restricted interests and highly repetitive behavior.|Severe distortions in the development of many basic psychological functions that are not normal for any stage in development. These distortions are manifested in sustained social impairment, speech abnormalities, and peculiar motor movements.|Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (DSM, 1994)
GWAS_EFO_1002011: adult onset asthma - Asthma that starts in adulthood
GWAS_EFO_0000249: obsolete_Alzheimer's disease - A dementia that results in progressive memory loss, impaired thinking, disorientation, and changes in personality and mood starting in late middle age and leads in advanced cases to a profound decline in cognitive and physical functioning and is marked histologically by the degeneration of brain neurons especially in the cerebral cortex and by the presence of neurofibrillary tangles and plaques containing beta-amyloid. It is characterized by memory lapses, confusion, emotional instability and progressive loss of mental ability.|A progressive, neurodegenerative disease characterized by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language.|A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)|A dementia which is an incurable disease of unknown cause, starting in late middle age or in old age, that results in progressive memory loss, impaired thinking, disorientation, and changes in personality and mood, that leads in advanced cases to a profound decline in cognitive and physical functioning, and that is marked histologically by the degeneration of brain neurons especially in the cerebral cortex and by the presence of neurofibrillary tangles and plaques containing beta-amyloid.
GWAS_EFO_0004579: serum IgE measurement - A serum immunoglobulin E measurement is the measurement of the IgE antibody isotype produced by plasma cells in response to an immunogen and which function as antibodies, measured in serum. IgE's main function is immunity to parasites such as parasitic worms and it plays an essential role in the allergy disorder, and is especially associated with type I hypersensitivity.
GWAS_EFO_0004980: appendicular lean mass - Appendicular lean mass is a measurement of skeletal strength of lower limbs and is used as a predictive measure of hip fracture.
GWAS_EFO_0000220: acute lymphoblastic leukemia - Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.
GWAS_EFO_0004881: asparaginase hypersensitivity - Is an allergy to asaparaginase. Asparaginase is an enzyme isolated from the bacterium Escherichia coli or the bacterium Erwinia carotovora with antileukemic activity
GWAS_EFO_0006797: neurofibrillary tangles measurement - quantification of the presence and amount of neurofibrillary tangles, pathological protein aggregates formed by hyperphosphorylation of a microtubule-associated protein known as tau
GWAS_EFO_0000311: cancer - A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.
GWAS_EFO_0004842: eosinophil count - Is a quantification of eosinphils in blood.|The number of granulocytes (polymorphonuclear leukocytes) in a specified volume of blood, usually 1 cubic millimeter.
GWAS_EFO_0004708: nodular sclerosis Hodgkin lymphoma - A subtype of classical Hodgkin lymphoma characterized by collagen bands that surround at least one nodule, and Hodgkin and Reed-Sternberg cells with lacunar type morphology. (WHO, 2008)
GWAS_EFO_0002690: systemic lupus erythematosus - An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific.|A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
GWAS_EFO_0004337: intelligence - The ability to learn and to deal with new situations and to deal effectively with tasks involving abstractions.
GWAS_EFO_0007989: monocyte percentage of leukocytes - A calculated measurement in which the number of monocytes in a specified sample of blood is divided by the total number of white blood cells in the sample, and the result presented as a ratio, fraction, quotient or percentage. 
GWAS_EFO_0000685: rheumatoid arthritis - Rheumatoid arthritis is a rheumatologic disorder described as an autoimmune disease that is usually a chronic disease and is characterized especially by pain, stiffness, inflammation, swelling, and sometimes destruction of joints.|A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.|A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.|An arthritis that results_from an autoimmune disease which attacks healthy cells and tissue located_in joint.
GWAS_EFO_0000096: neoplasm of mature B-cells - A neoplasm of follicle centre B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).|Editor note: is a non-hodgkin in ONCOTREE
GWAS_EFO_0004833: neutrophil count - Is a quantification of neutrophils in blood.|The number of granulocytes (polymorphonuclear leukocytes) in a specified volume of blood, usually 1 cubic millimeter.
GWAS_EFO_0004458: C-reactive protein measurement - C-reactive protein (CRP) measurement is a measurement of the level of C-reactive protein in the blood.  Levels are known to rise in response to inflammation, CRP is therefore used as a clinical measure of inflammation. The measurement is used in the process of clinical diagnosis as high levels of CRP are associated with cardiovascular disease, diabetes and hypertension and in some cancers.|is about MeSH:D002097
GWAS_EFO_0004612: high density lipoprotein cholesterol measurement - The measurement of HDL cholesterol in blood used as a risk indicator for heart disease.
GWAS_EFO_0007988: myeloid white cell count - The number of myeloid leukocytes in a specified volume of blood, usually 1 cubic millimeter.
GWAS_HP_0000726: Dementia - A loss of global cognitive ability of sufficient amount to interfere with normal social or occupational function. Dementia represents a loss of previously present cognitive abilities, generally in adults, and can affect memory, thinking, language, judgment, and behavior.
GWAS_EFO_0006801: Alzheimer's disease neuropathologic change - degenerative change that occurs in individuals with Alzheimer's disease, such as amyloid plaques, cerebral amyloid angiopathy, neurofibrillary tangles, neuronal loss or synaptic loss
GWAS_MONDO_0044887: central nervous system non-hodgkin lymphoma - A non-Hodgkin lymphoma that arises from the central nervous system.
GWAS_EFO_0009273: anti-Epstein Barr virus antibody measurement - Quantification of one or more antibodies to the Epstein-Barr virus, typically in serum
GWAS_EFO_0008002: physical activity measurement - quantification of some aspect of physical activity such as frequency or intensity
GWAS_EFO_0007788: BMI-adjusted waist-hip ratio - waist-hip ratio that has been adjusted by subjects’ body mass index
GWAS_EFO_0008579: risk-taking behaviour - The tendency to take risks. Risk-taking behaviour is a characteristic of several psychiatric disorders such as ADHD and bipolar disorder, as well as problem behaviours such as smoking and drug abuse.
GWAS_EFO_0001061: cervical carcinoma - A carcinoma arising from either the exocervical squamous epithelium or the endocervical glandular epithelium. The major histologic types of cervical carcinoma are: squamous carcinoma, adenocarcinoma, adenosquamous carcinoma, adenoid cystic carcinoma and undifferentiated carcinoma.
GWAS_EFO_0004305: erythrocyte count - The number of red blood cells per unit volume in a sample of venous blood.
GWAS_Orphanet_797: Sarcoidosis - Disease involving abnormal collections of inflammatory cells that form lumps known as granulomas. The disease usually begins in the lungs, skin, or lymph nodes.
GWAS_EFO_0010150: anti-anoctamin 2 antibody measurement - Quantification of antibodies against anoctamin 2.
GWAS_EFO_0004308: leukocyte count - The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
GWAS_EFO_0004343: waist-hip ratio - The waist circumference measurement divided by the hip circumference measurement. For both men and women, a waist-to-hip ratio (WHR) of 1.0 or higher is considered "at risk" for undesirable health consequences, such as heart disease and ailments associated with OVERWEIGHT. A healthy WHR is 0.90 or less for men, and 0.80 or less for women. (National Center for Chronic Disease Prevention and Health Promotion, 2004)
GWAS_EFO_0007924: tonsillectomy risk measurement - Quantification an individual's risk of undergoing tonsillectomy. Some individuals experience recurrent, severe tonsillitis and massive hypertrophy of the tonsils in which case surgical removal of the tonsils may be considered. There are a number of genetic variants that may reduce the risk of tonsillectomy by conferring a protective effect.
GWAS_EFO_0007791: rheumatoid factor seropositivity measurement - rheumatoid factor seropositivity is the result of a measurement of circulating  autoantibodies called rheumatoid factors that contribute to a number of autoimmune diseases including rheumatoid arthritis
GWAS_EFO_0007837: anti-citrullinated protein antibody seropositivity - anti-citrullinated protein antibody seropositivity is the result of a measurement of circulating anti-cyclic citrullinated peptide antibodies
GWAS_EFO_0009415: CCL19 measurement - Quantification of the amount of CCL19 protein in a sample.
GWAS_EFO_0007991: eosinophil percentage of leukocytes - A calculated measurement in which the number of eosinophil granulocytes is divided by the number of all white blood cells in a specified sample of peripheral venous blood, and the result presented as a ratio, fraction, quotient or percentage. An eosinophil is a granular leukocyte having a nucleus with two lobes connected by a thread of chromatin, and cytoplasm containing coarse, round granules of uniform size that stain readily with eosin and other acid dyes.
GWAS_EFO_0010762: advanced glycosylation end product-specific receptor ligand measurement - Quantification of the amount of advanced glycosylation end product-specific receptor ligand in a sample
GWAS_EFO_0004587: lymphocyte count - A quantification of lymphocytes in blood.
GWAS_EFO_0009785: remission - A disease stage which is characterized by the lack of a manifestation of a disease.
GWAS_EFO_0003047: hepatitis C virus infection - A viral hepatitis and is_a Hepacivirus infectious disease, that results_in inflammation located_in liver, has_agent Hepatitis C virus, which is transmitted_by blood from an infected person enters the body of an uninfected person. The infection has_symptom fever, has_symptom fatigue, has_symptom loss of appetite, has_symptom nausea, has_symptom vomiting, has_symptom abdominal pain, has_symptom clay-colored bowel movements, has_symptom joint pain, and has_symptom jaundice.|A viral infection caused by the hepatitis C virus.|A Hepacivirus infectious disease which is a chronic bloodborne infectious disease caused by Hepatitis C virus. The symptoms include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, clay-colored bowel movements, joint pain and jaundice.|A Hepacivirus infectious disease and is_a viral hepatitis that results_in inflammation located_in liver, has_agent Hepatitis C virus, which is transmitted_by blood from an infected person enters the body of an uninfected person. The infection has_symptom fever, has_symptom fatigue, has_symptom loss of appetite, has_symptom nausea, has_symptom vomiting, has_symptom abdominal pain, has_symptom clay-colored bowel movements, has_symptom joint pain, and has_symptom jaundice.
GWAS_EFO_0007790: Epstein Barr virus nuclear antigen 1 IgG measurement - measurement of the IgG antibody isotype produced by plasma cells in response to an Epstein Barr virus infection, specifically to the Epstein–Barr virus nuclear antigen 1
GWAS_EFO_0005413: joint damage measurement - quantification of the level of joint damage, eg through radiological analysis
GWAS_EFO_0007986: reticulocyte count - The number of reticulocytes per unit volume of blood. Reticulocytes are immature red blood cells and typically compose aoubt 1% of red blood cells in the human body.
GWAS_EFO_0004611: low density lipoprotein cholesterol measurement - The measurement of LDL cholesterol in blood used as a risk indicator for heart disease.
GWAS_EFO_0004574: total cholesterol measurement - A total cholesterol measurement is the quantification of cholesterol in blood, total cholesterol is defined as the sum of HDL, LDL, and VLDL.
GWAS_EFO_0004778: self rated health - The process of questioning an individual, usually by means of a survey to determine general health.
GWAS_EFO_0006941: grip strength measurement - quantification of the force applied by the hand to pull on or suspend from objects
GWAS_EFO_0005090: basophil count - quantification of basophils in the blood|The number of granulocytes (polymorphonuclear leukocytes) in a specified volume of blood, usually 1 cubic millimeter.
GWAS_EFO_0009262: nicotine dependence symptom count - Quantification of symptom associated with nicotine dependence.
GWAS_EFO_0010220: 17-hydroxyprogesterone measurement - Quantification of the amount of 17-hydroxyprogesterone in a sample
GWAS_EFO_0006798: neuritic plaque measurement - quantification of  neuritic (senile) plaques in the brain, Senile plaques (also known as neuritic plaques, senile druse and braindruse) are extracellular deposits of amyloid beta in the grey matter of the brain.[1][2] Degenerative neural structures and an abundance of microglia and astrocytes can be associated with senile plaque deposits. These deposits can also be a byproduct of senescence (ageing). However, large numbers of senile plaques and neurofibrillary tangles are characteristic features of Alzheimer's disease. Abnormal neurites in senile plaques are composed primarily of paired helical filaments, a component of neurofibrillary tangles.[3] The plaques are variable in shape and size, but are on average 50 µm in size.[4] In Alzheimer's disease they are primarily composed of amyloid beta peptides.
GWAS_EFO_0004696: sex hormone-binding globulin measurement - Is a quantification of sex hormone binding globulin. In men the test is used in when investigating testosterone deficiency.  The SHBG glycoprotein binds to circulating estradiol and testosterone, low levels of SHBG may be implicated in breast cancer etiology.
GWAS_Orphanet_3389: Tuberculosis - that in most individuals is usually asymptomatic but that in at risk individuals (e.g. with diabetes or with HIV infection) can cause weakness, fever, weight loss, night sweat, and respiratory anomalies such as chronic cough, chest pain, hemoptysis or respiratory insufficiency.
GWAS_EFO_0004530: triglyceride measurement - A triglyceride  measurement is a quantification of triglycerides in some body fluid, used as a biomarker for cardiovascular disease.
GWAS_EFO_0005091: monocyte count - quantification of monocytes in the blood
GWAS_EFO_0004645: response to vaccine - Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vaccine. A vaccine is a preparationcontaining substances with antigenic properties administered to activate the immune system, thereby inducing an immune response.
GWAS_EFO_1000811: anterior uveitis - Inflammation of the iris and anterior chamber of the eye.|Inflammation of the anterior uvea comprising the iris, angle structures, and the ciliary body. Manifestations of this disorder include ciliary injection, exudation into the anterior chamber, iris changes, and adhesions between the iris and lens (posterior synechiae). Intraocular pressure may be increased or reduced.
GWAS_EFO_0007187: bullous pemphigoid - An autoimmune disease of skin and connective tissue characterized by large blisters.|Bullous pemphigoid (BP) is the most common form of autoimmune bullous dermatosis.
GWAS_EFO_0004526: mean corpuscular volume - A mean corpuscular volume is the result of calculation of the mean volume of erythrocytes in a blood sample.
GWAS_EFO_0004614: apolipoprotein A 1 measurement - Is a quantification of serum lipoprotein A. Apolipoprotein A-I, encoded in humans by the APOA1 gene and  is the major protein component of high density lipoprotein (HDL) in plasma.   It is is implicated as a risk factor for atherosclerotic diseases such as coronary heart disease and stroke.
GWAS_EFO_0004695: intraocular pressure measurement - Is a quantification of intraocular pressure. Increased intraocular pressure is a heritable risk factor for primary open angle glaucoma.
GWAS_EFO_0001075: ovarian carcinoma - A malignant neoplasm originating from the surface ovarian epithelium. It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women. It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups. Adenocarcinomas constitute the vast majority of ovarian carcinomas. The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type. The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver. Lung and pleura are the most common sites of extra-abdominal spread. The primary form of therapy is surgical. The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms. --2002|Editor note: unclear why this is distinct from malignant ovarian epithelial tumor in NCIT.
GWAS_EFO_1001490: late-onset myasthenia gravis - late-onset myasthenia gravis is a form of MG that occurs in individuals aged 50 years or older|Acquired myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction characterized by fatigable muscle weakness with frequent ocular signs and/or generalized muscle weakness, and occasionally associated with thymoma.
GWAS_EFO_0003885: obsolete_multiple sclerosis - An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
GWAS_EFO_0005206: oligoclonal band measurement - detection or quantification of bands of immunoglobulins in blood serum or cerebrospinal fluid, usually as an indicator of central nervous system disorders such as multiple sclerosis, Lyme disease, systemic lupus erythematosus or neurosarcoidosis
GWAS_EFO_0004193: basal cell carcinoma - A carcinoma involving the basal cells.
GWAS_EFO_0004556: antibody measurement - Is the quantification of some antibody
GWAS_EFO_0007009: skin pigmentation measurement - quantification of some aspect of skin pigmentation, such as saturation, darkness or skin sensitivity to sun
GWAS_EFO_0007993: lymphocyte percentage of leukocytes - A calculated measurement in which the number of lymphocytes in a specified sample of blood is divided by the total number of white blood cells in the sample, and the result presented as a ratio, fraction, quotient or percentage. 
GWAS_EFO_0007990: neutrophil percentage of leukocytes - A calculated measurement in which the number of neutrophil granulocytes is divided by the number of all white blood cells in a specified sample of peripheral venous blood, and the result presented as a ratio, fraction, quotient or percentage. A neutrophil is, or is in the process of becoming, a granular leucocyte having a nucleus with three to five lobes connected by threads of chromatin, cytoplasm containing very fine granules, and which is readily stainable with neutral dyes.
GWAS_EFO_1001489: skin and soft tissue Staphylococcus aureus infection - Staphylococcus aureus infection that occurs specifically in skin or soft tissue and manifests through a specific range of symptoms including but not necesarrily limited to erysipelas, cellulitis, abscesses, mastitis, carbuncle and furuncle, acute lymphadenitis, impetigo, folliculitis and hidradenitis 
GWAS_EFO_0005681: Staphylococcus aureus infection - Staphylococcus aureus infection is a bacterial disease caused by infection from the Staphylococcus aureus bacteria.|An infectious process in which the bacteria Staphylococcus aureus is present.
GWAS_EFO_0006336: diastolic blood pressure - The blood pressure after the contraction of the heart while the chambers of the heart refill with blood.
GWAS_EFO_0004348: hematocrit - The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value.
GWAS_EFO_0004509: hemoglobin measurement - hemoglobin levels|Hemoglobin measurement is a measure of the quantity of the metallo protein hemoglobin in blood often used in the diagnosis of anaemia.
GWAS_EFO_0004255: nephrotic syndrome - A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.|A collection of symptoms that include severe edema, proteinuria, and hypoalbuminemia; it is indicative of renal dysfunction.
GWAS_EFO_0004533: alkaline phosphatase measurement - Alkaline phosphatase measurement is a quantification of alkaline phosphatase in blood. AP is a marker for bone and liver disease.


#ENTITY MAPPING:
GENETIC ENTITIES AND THEIR ASSOCIATED GWAS:
Entity: Gene (ID: 16140717) -> Associated GWAS: GWAS_EFO_0000270, GWAS_EFO_0007937, GWAS_EFO_0007937, GWAS_EFO_0007034, GWAS_EFO_0007969, GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1002011, GWAS_EFO_0000249, GWAS_EFO_0004579, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0004980, GWAS_EFO_0000220, GWAS_EFO_0004881, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1002011, GWAS_EFO_0006797, GWAS_EFO_0000311, GWAS_EFO_0004842, GWAS_EFO_0000692, GWAS_EFO_0003756
Entity: Transcript (ID: 16231095) -> Associated GWAS: GWAS_EFO_0000270, GWAS_EFO_0007937, GWAS_EFO_0007937, GWAS_EFO_0007034, GWAS_EFO_0007969, GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1002011, GWAS_EFO_0000249, GWAS_EFO_0004579, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0004980, GWAS_EFO_0000220, GWAS_EFO_0004881, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1002011, GWAS_EFO_0006797, GWAS_EFO_0000311, GWAS_EFO_0004842, GWAS_EFO_0000692, GWAS_EFO_0003756
Entity: Non Coding RNA (ID: 17329082) -> Associated GWAS: GWAS_EFO_0000270, GWAS_EFO_0004708, GWAS_EFO_0002690, GWAS_EFO_0004337, GWAS_EFO_0007989, GWAS_EFO_0000685, GWAS_EFO_0000096, GWAS_EFO_0004833, GWAS_EFO_0004458, GWAS_EFO_0004612, GWAS_EFO_0007988, GWAS_HP_0000726, GWAS_EFO_0006801, GWAS_EFO_0000311, GWAS_MONDO_0044887, GWAS_EFO_0009273, GWAS_EFO_0008002, GWAS_EFO_0007788, GWAS_EFO_0008579, GWAS_EFO_0000685, GWAS_EFO_0001061, GWAS_EFO_0004305, GWAS_MONDO_0044887, GWAS_Orphanet_797, GWAS_EFO_0010150, GWAS_EFO_0002690, GWAS_EFO_0001061, GWAS_EFO_0004308, GWAS_EFO_0007788, GWAS_EFO_0004343, GWAS_EFO_0007924, GWAS_EFO_0002690, GWAS_EFO_0007791, GWAS_EFO_0007837, GWAS_EFO_0000685, GWAS_EFO_0009415, GWAS_EFO_0007989, GWAS_EFO_0007991, GWAS_EFO_0010762, GWAS_EFO_0004587, GWAS_EFO_0009785, GWAS_EFO_0003047, GWAS_EFO_0007937, GWAS_EFO_0004833, GWAS_EFO_0007790, GWAS_EFO_0005413, GWAS_EFO_0000685, GWAS_EFO_0000685, GWAS_EFO_0007986, GWAS_EFO_0007937, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0007937, GWAS_EFO_0000270, GWAS_EFO_0004611, GWAS_EFO_0004574, GWAS_EFO_0004778, GWAS_EFO_0007937, GWAS_EFO_0006941, GWAS_EFO_0005090, GWAS_EFO_0007937, GWAS_EFO_0009262, GWAS_EFO_0010220, GWAS_EFO_0007937, GWAS_EFO_0006798, GWAS_EFO_0006797, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000270, GWAS_EFO_0010220, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0007937, GWAS_EFO_0004696, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_Orphanet_3389, GWAS_EFO_0004530, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0004587, GWAS_EFO_0005091, GWAS_EFO_0004645, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0007937, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0006941, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1000811, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0004587, GWAS_EFO_0005091, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0004612, GWAS_EFO_0000685, GWAS_EFO_0007187, GWAS_EFO_0007937, GWAS_EFO_0000692, GWAS_EFO_0004526, GWAS_EFO_0003756, GWAS_EFO_0007937, GWAS_EFO_0004614, GWAS_EFO_0004695, GWAS_EFO_0009262, GWAS_EFO_0001075, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1001490, GWAS_EFO_0003885, GWAS_EFO_0005206, GWAS_EFO_0004193, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0004556, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0007009, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0004556, GWAS_EFO_0007937, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0007993, GWAS_EFO_0007990, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000270, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1001489, GWAS_EFO_0005681, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000270, GWAS_EFO_0007937, GWAS_EFO_0006941, GWAS_EFO_0007937, GWAS_EFO_0000270, GWAS_EFO_0007937, GWAS_EFO_0007937, GWAS_EFO_0007034, GWAS_EFO_0007969, GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1002011, GWAS_EFO_0000249, GWAS_EFO_0004579, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0004980, GWAS_EFO_0000220, GWAS_EFO_0004881, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1002011, GWAS_EFO_0006797, GWAS_EFO_0000311, GWAS_EFO_0004842, GWAS_EFO_0000692, GWAS_EFO_0003756
Entity: Non Coding RNA (ID: 17329101) -> Associated GWAS: GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000270, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1001489, GWAS_EFO_0005681, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000270, GWAS_EFO_0007937, GWAS_EFO_0006941, GWAS_EFO_0007937, GWAS_EFO_0000270, GWAS_EFO_0007937, GWAS_EFO_0007937, GWAS_EFO_0007034, GWAS_EFO_0007969, GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1002011, GWAS_EFO_0000249, GWAS_EFO_0004579, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0004980, GWAS_EFO_0000220, GWAS_EFO_0004881, GWAS_EFO_0000692, GWAS_EFO_0003756
Entity: Non Coding RNA (ID: 17329096) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: Non Coding RNA (ID: 17329097) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 300587196) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 297770058) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756
Entity: TF Binding Site (ID: 296536503) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 294164833) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 288996702) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 282454577) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 276575911) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 275174211) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 269015989) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 264293871) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 261268566) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 244926088) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 243796496) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756
Entity: TF Binding Site (ID: 243677200) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 238315802) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756
Entity: TF Binding Site (ID: 232920799) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 232433463) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 227614502) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 227196806) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964
Entity: TF Binding Site (ID: 211600736) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 208026769) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 205594779) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 197976323) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756
Entity: TF Binding Site (ID: 196458582) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 189648570) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 182292807) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 182253426) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756
Entity: TF Binding Site (ID: 181723745) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 175286082) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 162705797) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756
Entity: TF Binding Site (ID: 147368520) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 145308299) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 140977074) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756
Entity: TF Binding Site (ID: 138125264) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 133625682) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 124977412) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 118715798) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 116982597) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 116512982) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 115888414) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756
Entity: TF Binding Site (ID: 115092119) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 107474420) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: TF Binding Site (ID: 96065548) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756
Entity: TF Binding Site (ID: 94557959) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: Histone Modification Site (ID: 88697643) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: Histone Modification Site (ID: 58857754) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1002011, GWAS_EFO_0000249
Entity: ChromHMM State (ID: 22682387) -> Associated GWAS: GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0007993, GWAS_EFO_0007990, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000270, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1001489, GWAS_EFO_0005681, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000270, GWAS_EFO_0007937, GWAS_EFO_0006941, GWAS_EFO_0007937, GWAS_EFO_0000270, GWAS_EFO_0007937, GWAS_EFO_0007937, GWAS_EFO_0007034, GWAS_EFO_0007969, GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1002011, GWAS_EFO_0000249, GWAS_EFO_0004579, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0004980, GWAS_EFO_0000220, GWAS_EFO_0004881, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1002011, GWAS_EFO_0006797, GWAS_EFO_0000311, GWAS_EFO_0004842, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0002690, GWAS_EFO_0006336, GWAS_EFO_0004348, GWAS_EFO_0004305, GWAS_EFO_0004509, GWAS_EFO_0007986, GWAS_EFO_0007937, GWAS_EFO_0007937, GWAS_EFO_0004255, GWAS_EFO_0006941, GWAS_EFO_0004458, GWAS_EFO_0006941, GWAS_EFO_0004612, GWAS_EFO_0004833, GWAS_EFO_0004533
Entity: ChromHMM State (ID: 22086479) -> Associated GWAS: GWAS_EFO_0006941, GWAS_EFO_0007937, GWAS_EFO_0000270, GWAS_EFO_0007937, GWAS_EFO_0007937, GWAS_EFO_0007034, GWAS_EFO_0007969, GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1002011, GWAS_EFO_0000249
Entity: ChromHMM State (ID: 21458334) -> Associated GWAS: GWAS_EFO_0007009, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0004556, GWAS_EFO_0007937, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0007993, GWAS_EFO_0007990, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000270, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1001489, GWAS_EFO_0005681, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000270, GWAS_EFO_0007937, GWAS_EFO_0006941, GWAS_EFO_0007937, GWAS_EFO_0000270, GWAS_EFO_0007937, GWAS_EFO_0007937, GWAS_EFO_0007034, GWAS_EFO_0007969, GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1002011, GWAS_EFO_0000249, GWAS_EFO_0004579, GWAS_EFO_0000692, GWAS_EFO_0003756
Entity: ChromHMM State (ID: 20849739) -> Associated GWAS: GWAS_EFO_0000270, GWAS_EFO_0007937, GWAS_EFO_0007937, GWAS_EFO_0007034, GWAS_EFO_0007969, GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1002011, GWAS_EFO_0000249, GWAS_EFO_0004579
Entity: ChromHMM State (ID: 20259870) -> Associated GWAS: GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: ChromHMM State (ID: 19699953) -> Associated GWAS: GWAS_EFO_0000270, GWAS_EFO_0007937, GWAS_EFO_0007937, GWAS_EFO_0007034, GWAS_EFO_0007969, GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1002011
Entity: ChromHMM State (ID: 19110447) -> Associated GWAS: GWAS_EFO_0007937, GWAS_EFO_0007034, GWAS_EFO_0007969, GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270
Entity: chr_chain (ID: 286476) -> Associated GWAS: GWAS_EFO_0007937, GWAS_EFO_0007034, GWAS_EFO_0007969, GWAS_EFO_0005854, GWAS_HP_0000964, GWAS_EFO_0000270, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_1002011, GWAS_EFO_0000249, GWAS_EFO_0004579, GWAS_EFO_0000692, GWAS_EFO_0003756, GWAS_EFO_0004980, GWAS_EFO_0000220, GWAS_EFO_0004881, GWAS_EFO_0000692, GWAS_EFO_0003756


#CLINVAR INFO:

CLINVAR PATHOGENICITY SUMMARY:
==============================
• Total ClinVar variants analyzed: 569
• Pathogenic/Likely Pathogenic: 19
• Benign/Likely Benign: 404
• Uncertain Significance: 144
• Other Classifications: 2
ASSOCIATED PHENOTYPES/DISEASES (NON-BENIGN VARIANTS):
====================================================
• Multiple sclerosis, susceptibility to (n=25)
• Peritoneal Gliomatosis|not provided (n=8)
• Pulmonary artery atresia (n=8)
• Small for gestational age (n=2)


